Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IBIO-600 (Myostatin Antibody) in Cardiometabolic Diseases. The expected timing is based on the latest available company guidance and may change.
02/10/26:- Completing toxicology studies; on track to enter Ph1a trials in H1 2026. 04/08/26:- Australia TGA CTN and ethics approvals received; first Ph1 participant expected dosed in Q2 2026. 05/12/26:- CTN and HREC clear Phase 1 IBIO-600 trial; first overweight and obese participant dosing expected Q2 2026. 06/02/26:- First Ph1 participant dosed. Phase 1 study completion expected in H2 2027.
Verification
Confirm timing and program details against the company announcement or filing.